PubRank
Search
About
Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)
Clinical Trial ID NCT00600587
PubWeight™ 44.88
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT00600587
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
N Engl J Med
2009
46.35
2
Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.
J Thorac Oncol
2007
2.15
3
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.
Lung Cancer
2007
1.87
4
Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation.
Lung Cancer
2007
1.03
5
Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer.
J Clin Oncol
2008
0.91
6
Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status.
J Hematol Oncol
2015
0.87
7
Treatment of stage IIIA non-small cell lung cancer.
Chest
2003
0.85
8
Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients.
Onco Targets Ther
2014
0.80
Next 100